Newron Pharmaceuticals S.p.A. Stock
Stocks
NWRN
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
08:15:18 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 12.31 CHF | +0.90% |
|
-4.06% | -48.51% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 271M 317M 254M 232M 438M 30.32B 443M 3B 1.17B 15.22B 1.19B 1.16B 50.37B | P/E 2026 * |
-9.61x | P/E 2027 * | 35.2x |
|---|---|---|---|---|---|
| Enterprise Value | 310M 362M 290M 265M 500M 34.64B 506M 3.43B 1.33B 17.39B 1.36B 1.33B 57.55B | EV / Sales 2026 * |
28.6x | EV / Sales 2027 * | 6.38x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | +0.90% | ||
| 1 week | -4.06% | ||
| Current month | +5.32% | ||
| 1 month | +2.68% | ||
| 3 months | -13.40% | ||
| 6 months | -36.04% | ||
| Current year | -48.51% |
| 1 week | 12.1 |  | 13.44 |
| 1 month | 11.48 | | 13.44 |
| Current year | 11.24 | | 31.85 |
| 1 year | 8.05 | | 31.85 |
| 3 years | 4.09 | | 31.85 |
| 5 years | 1.01 | | 31.85 |
| 10 years | 0.9 | | 31.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 2012-05-14 |
Roberto Galli
DFI | Director of Finance/CFO | - | 2011-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 2012-05-14 |
Gillian Dines
BRD | Director/Board Member | - | 2023-03-31 |
Margarita Chavez
BRD | Director/Board Member | - | 2024-04-16 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/12/26 | Buy | Chief Executive Officer | 2,000 | 0.0096% | ||
| 8/11/26 | Buy | Chief Technology Officer | 582 | 0.0028% | ||
| 8/10/26 | Buy | Chief Technology Officer | 1,418 | 0.0068% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.90% | -4.06% | +42.96% | +130.83% | 317M | |
| +1.12% | +5.16% | +3.88% | +25.71% | 51.21B | |
| +1.01% | -0.20% | +471.68% | +564.93% | 45.35B | |
| +0.16% | +7.88% | +36.14% | +20.76% | 42.84B | |
| -0.66% | +2.61% | +18.59% | +87.04% | 42.29B | |
| +0.88% | -3.48% | +17.20% | +53.83% | 32.15B | |
| -0.12% | +3.84% | +33.73% | +145.25% | 17.31B | |
| -0.53% | +1.84% | - | - | 16.55B | |
| +0.33% | +5.51% | +10.13% | +31.58% | 14.84B | |
| +1.15% | +4.17% | +84.49% | +50.33% | 14.25B | |
| Average | +0.41% | +2.48% | +79.87% | +123.36% | 27.71B | |
| Weighted average by Cap. | +0.41% | +3.07% | +101.43% | +141.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.65M 10.14M 9.27M 17.5M 1.21B 17.69M 120M 46.67M 608M 47.51M 46.48M 2.01B | 44.83M 52.31M 41.94M 38.34M 72.36M 5.01B 73.13M 496M 193M 2.52B 196M 192M 8.32B |
| Net income | -31.17M -36.38M -29.16M -26.66M -50.32M -3.48B -50.85M -345M -134M -1.75B -137M -134M -5.79B | 5.02M 5.86M 4.7M 4.3M 8.11M 561M 8.19M 55.61M 21.62M 282M 22.01M 21.53M 932M |
| Net Debt | 38.68M 45.14M 36.19M 33.09M 62.44M 4.32B 63.1M 428M 167M 2.17B 169M 166M 7.18B | 14.72M 17.17M 13.77M 12.59M 23.75M 1.64B 24.01M 163M 63.35M 826M 64.48M 63.08M 2.73B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-25 | CHF 12.28 | +0.66% | 7,667 |
| 26-08-24 | CHF 12.20 | -2.71% | 35,206 |
| 26-08-21 | CHF 12.54 | -0.32% | 33,073 |
| 26-08-20 | CHF 12.58 | -2.93% | 86,719 |
| 26-08-19 | CHF 12.96 | +1.25% | 49,841 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
Select your edition
All financial news and data tailored to specific country editions
